TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04426591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biotin Labeled Red Blood Cells
Description: On the day of transfusion, a 20 mL aliquot will be sterilely withdrawn from each RBC unit, washed and labeled with sulfo-NHS-biotin for 30 minutes, washed to stop the labeling reaction, then resuspended in plasma to a hematocrit of \~60%. The biotin-labeled RBC (BioRBC) will be transfused along with the remainder of the RBC unit (unlabeled volume). Standard blood bank and CTT protocols and minor antigen matching for SCD patients will be followed. Exact transfusion volume will be determined based on pre-transfusion hemoglobin (Hb), sickle cell hemoglobin (HbS), and body weight, per clinical protocol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTERCEPT Blood System
Description: In addition to the blood drawn for the main study, individuals participating in this optional intervention will have additional tubes of peripheral venous blood will be drawn for evaluating treatment-emergent antibodies specific to INTERCEPT RBCs and acridine surface label monitoring. Tests for treatment-emergent antibodies specific to INTERCEPT RBCs will be performed according to procedures developed by Cerus Corporation.
Study: NCT06747702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injury prevention workout
Description: The injury prevention workout consisted on engaging on a prevention program from 1 day to 8 weeks where the participants will develop functional sport exercises to prevent shoulder injuries or pain in overhead sports.
Study: NCT06747676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active: High-Definition transcranial Direct Current Stimulation (HD-tDCS)
Description: Active high-definition transcranial direct current stimulation (HD-tDCS) will be delivered by a low-intensity direct current stimulator (Soterix Medical) using a 3x1 ring configuration with a central cathode over the contralesional temporo-parietal junction. During the stimulation, participants will perform tasks to stimulate correct visual verticality perception. Six active HD-tDCS sessions of 2mA for 20 minutes HD-tDCS, 3 times daily for 2 days with session intervals greater than 3 hours.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham: High-Definition transcranial Direct Current Stimulation (HD-tDCS)
Description: Six sessions (3 times daily for 2 days) of 2mA sham HD-tDCS cathode center over the contralesional TPJ for 20min. Direct current (DC) will be generated by a low-intensity direct current stimulator (Soterix Medical) and then split into the 3 high-density Ag/AgCl sintered ring electrodes. The sham stimulation condition will consist of the same positioning of the electrodes as the active condition, with a ramp-up to 2mA over 30 seconds and a subsequent ramp-down of 30 seconds.
Study: NCT04747457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Research FibroScan
Description: After having obtained the patient's Informed Consent Form signature, the following 3 examinations will be done:~1. Standard examination \[Reference CE-marked FibroScan\]: the operator will need to find an optimal measurement area, and perform 10 valid measurements.~2. Standard examination \[Research FibroScan\]: the operator must take 15 valid measurements at the same measurement point as the one used for the examination with the Reference FibroScan.~3. Exploratory examination \[Research FibroScan\]: the operator needs to perform15 invalid measurements to acquire data in non-optimal regions of measurement (lungs, vessels, intestines, ribs, edges of the liver).
Study: NCT05193630

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milnutri Sure™
Description: Milnutri Sure™, a commercially available oral nutritional support (ONS) product in powder format, for children of 1 y of age and above (1.0 kcal /ml).~For children between 1 and 3 years of age, the recommendation is to use 2 servings per day, and for children from 4 to 6 years of age, the recommendation is to give 3 servings per day. One serving contains of 45 grams of product and 180 ml water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milnutri Sure™
Description: Milnutri Sure™, a commercially available oral nutritional support (ONS) product in powder format, for children of 1 y of age and above (1.0 kcal /ml).~For children between 1 and 3 years of age, the recommendation is to use 2 servings per day, and for children from 4 to 6 years of age, the recommendation is to give 3 servings per day. One serving contains of 45 grams of product and 180 ml water.
Study: NCT06747663

Intervention type: PROCEDURE
Intervention: Needle Depth Measurement Using MRI, Ultrasound, and Fluoroscopy
Description: This intervention involves cervical epidural steroid injection (CESI) for patients with chronic neck and radicular pain. Needle depth is measured pre-procedurally using MRI and ultrasound to predict the ideal needle placement. Fluoroscopy is used during the procedure to confirm and compare these measurements, aiming to evaluate the accuracy of imaging techniques and minimize radiation exposure.
Study: NCT06746506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Amigurumi toy
Description: A toy prepared using anti-allergic yarn to suit children's developmental stages.
Study: NCT06218914

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NT-112: Autologous, engineered T Cells targeting KRAS G12D
Description: * Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide~* Single infusion of T cell receptor (TCR) T cells~* Post-infusion recombinant interleukin-2 (rIL-2)
Study: NCT03268070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive TMS over contralateral premotor cortex.
Description: Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive TMS over ipsilateral premotor cortex.
Description: Repetitive Transcranial magnetic stimulation (rTMS) will be applied over ipsilateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive TMS over contralateral primary motor cortex.
Description: Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral primary motor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain.Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive TMS over contralateral premotor cortex.
Description: Sham rTMS will be applied over contralateral premotor cortex. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single TMS over extensor carpi ulnaris spot of motor cortex
Description: Single-pulse TMS will be applied over the extensor carpi ulnaris (ECU) hotspot of primary motor cortex (M1) during motor training.TMS uses magnetism to excite neurons near the surface of the brain. TMS pulses will be applied at different strengths (30%-80% maximum stimulator output) and record subsequent activity of the ECU muscle using electromyography (EMG).
Study: NCT05647811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM8074
Description: NM8074 will be administered as an intravenous infusion. Multiple dosing duration will range from 5 to 9 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM8074
Description: NM8074 will be administered as an intravenous infusion. Multiple dosing duration will range from 5 to 9 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM8074
Description: NM8074 will be administered as an intravenous infusion. Multiple dosing duration will range from 5 to 9 weeks.
Study: NCT05130333

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04717375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR444881
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR444881
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR444881
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR444881
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR444881
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pharmaceutical form: Powder for concentrate for solution for infusion or concentrate for solution for infusion; Route of administration: Intravenous
Study: NCT05678465

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-fixation of the mesh
Description: 3D-shaped, anatomical, standard, polypropylene mesh without fixation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fixation of the mesh
Description: Glue fixation of lightweight, macroporous, polypropylene mesh.
Study: NCT06575153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART5803
Description: A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART5803
Description: A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART5803
Description: A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART5803
Description: A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART5803
Description: A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.
Study: NCT06486064

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: heat-treated Limosilactobacillus fermentum
Description: one capsule daily for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one capsule daily for 8 weeks
Study: NCT06572293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention
Description: Nurse-led intervention involves patient education, collecting Patient Reported Outcomes (PRO) and evaluating them by specialists nurses, as well as navigating patients to services that can assist with their symptoms. During three-five planned appointments, the nurse will talk with you about adjusting to life after complete the radiotherapy of nasopharyngeal carcinoma, including symptoms of relapse and how to deal with them.In the first year, PROs will be collected every six months on recurrences and late effects, and thereafter every 12 months. PRO will be administered to patients for three years after the nurse appointments are finalized.
Study: NCT06645184

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral nutritional supplement
Description: During 4 test days, 1 bottle (125ML) of High protein ONS with or without fibre and with or without the added nutrients will be consumed by the subjects. During each test day, the subjects will complete questionnaires related to appetite and liking of the product from baseline (-5 minutes of start consumption of study product) until 120 minutes after start consumption of study product.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral nutritional supplement
Description: During 4 test days, 1 bottle (125ML) of High protein ONS with or without fibre and with or without the added nutrients will be consumed by the subjects. During each test day, the subjects will complete questionnaires related to appetite and liking of the product from baseline (-5 minutes of start consumption of study product) until 120 minutes after start consumption of study product.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral nutritional supplement
Description: During 4 test days, 1 bottle (125ML) of High protein ONS with or without fibre and with or without the added nutrients will be consumed by the subjects. During each test day, the subjects will complete questionnaires related to appetite and liking of the product from baseline (-5 minutes of start consumption of study product) until 120 minutes after start consumption of study product.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral nutritional supplement
Description: During 4 test days, 1 bottle (125ML) of High protein ONS with or without fibre and with or without the added nutrients will be consumed by the subjects. During each test day, the subjects will complete questionnaires related to appetite and liking of the product from baseline (-5 minutes of start consumption of study product) until 120 minutes after start consumption of study product.
Study: NCT06531083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early physical therapy intervention
Description: Physical therapy including manual therapy, home exercises for the neck and jaw, and use of a jaw stretching device.
Study: NCT05154734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be intravenously administered with a dose of 10mg/kg on Days 0,14 and28, then every 28 days until week 48, with a final evaluation at week 52.
Study: NCT06407297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCMSCs
Description: Peripheral intravenous infusion of umbilical cord mesenchymal stem cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Peripheral intravenous infusion of Placebo
Study: NCT05039281

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study: NCT04795960

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low serine diet
Description: Participants will be on this diet 1 week prior to initiation and 1 week after initiation of Ustekinumab (standard of care medication). The meals will be prepared in the Michigan Clinical Research Unit (MCRU) at the University of Michigan Health System and given to the participants.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High serine diet
Description: Participants will be on this diet 1 week prior to initiation and 1 week after initiation of Ustekinumab (standard of care medication). The meals will be prepared in the Michigan Clinical Research Unit (MCRU) at the University of Michigan Health System and given to the participants.
Study: NCT05039281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO
Study: NCT05913674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified early post-operative intraperitoneal chemotherapy (mEPIC)
Description: On post-operative days 1 and 2, an abdominal reservoir is obtained by administering 1000 mL of plasmalyte with 50 mEq NaHCO3 via a Tenckhoff catheter. Participants will then receive an intraperitoneal fluorouracil bolus of 400 mg/m2 administered over 1 to 2 minutes followed by a continuous intraperitoneal fluorouracil infusion of 1200 mg/m2 over the next 24 hours. During the continuous intraperitoneal infusion of fluorouracil, 50 mg of folinic acid is administered intravenously.~After completion of mEPIC day 1, the perfusate is drained out before starting mEPIC day 2.
Study: NCT06563765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAP-targeting PET/CT imaging will be performed on the enrolled patients.
Description: FAP-targeting PET/CT imaging will be performed on the enrolled patients.
Study: NCT05219175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA Assisted Therapy
Description: The intervention is MDMA Assisted Therapy focused on PTSD and three experiment sessions with the first session using an initial dose of 100 mg MDMA HCL (\~80 mg MDMA) with supplemental dose of 40 mg MDMA HCL (\~35 mg MDMA). Total dose range for the first session is 100 mg MDMA HCL (\~80 mg MDMA) to 140 mg MDMA HCL (\~115 mg MDMA).The second and third sessions may use an initial dose of 120 mg MDMA HCL (\~100 mg MDMA) with a supplemental dose of 60 mg MDMA HCL (\~50 mg MDMA) for a total dose range of 120 mg MDMA HCL (\~100 mg MDMA) to 180 mg MDMA HCL (\~160 mg MDMA)~Total cumulative dose range for the three sessions is 340mg MDMA HCL (\~280 mg MDMA) to 500 mg MDMA HCL (\~435 mg MDMA)
Study: NCT06426810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrosurgical bipolar system (LigaSure)
Description: Study participants using a electrosurgical bipolar energy system will undergo sentinel lymph node biopsy using only LigaSure during the surgery.
Study: NCT06045884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sono-guided injection
Description: After general anesthesia, patients will be injected around femoral nerve using ultrasonography.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sono-guided injection
Description: After general anesthesia, patients will be injected around femoral nerve using ultrasonography.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: After general anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: After general anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
Study: NCT04927143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App-Based Contingency Management
Description: Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App-Based Contingency Management
Description: Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App-Based Contingency Management
Description: Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App-Based Contingency Management
Description: Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App-Based Contingency Management
Description: Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App-Based Contingency Management
Description: Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham Control
Description: Participants get access to the DynamiCare app but will not be provided with financial incentives.
Study: NCT05072769

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Date Fruit
Description: Within the first hour after birth, 100gr (5-6 pieces) dates will be eaten.
Study: NCT05022368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LabraGuard
Description: Protection of the lips and the oral commissure during transoral procedures
Study: NCT04414787

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PCplanner
Description: PCplanner-augmented care. The PCplanner mobile app will allow patients / family members to report their needs in a platform viewable by ICU physicians. Should the needs not improve over time, the palliative care team will be activated to contribute to care.
Study: NCT06430918

Intervention type: OTHER
Intervention: physical examination, questionnaires and inventories
Description: Questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
Study: NCT04939116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG-3070
Description: Orally administered tyrosine kinase inhibitor capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG-3070
Description: Orally administered tyrosine kinase inhibitor capsule
Study: NCT06463717

Intervention type: DRUG
Intervention: Transplant, Autologous
Description: High-dose melphalan followed by autologous stem cell transplantation

Intervention type: DRUG
Intervention: Chemotherapy drug
Description: Regimen such as Bortezomib plus Lenalidomide plus Dexamethasone